Sam Clark

Oct 8, 2024 | hcplive.com | Sam Clark |Andrew Cutler

The recent approval of new schizophrenia treatments, such as xanomeline and tropsium chloride capsules (Cobenfy, formerly KarXT), signals a transformative shift in psychopharmacology, ushering in what leading subject matter experts are calling the "third wave" of drug development.

Oct 8, 2024 | hcplive.com | Sam Clark |Andrew Cutler

In this segment of our latest HCPLive Special Report on the recent approval of xanomeline and tropism chloride capsules (Cobenfy) for schizophrenia, conversation shifts to the critical issue of medication adherence in patients with schizophrenia. Research has indicated that adherence rates for oral medications have dropped below 50%.

Oct 8, 2024 | hcplive.com | Sam Clark |Andrew Cutler

On September 26, 2024, the US Food and Drug Administration (FDA) approved xanomeline and tropism chloride capsules (Cobenfy), backed by evidence in phase 3 EMERGENT trials. The approval marks the start of a new era in the management of schizophrenia, as the agent, formerly known as KarXT, marks the first new pharmacological approach to treating schizophrenia since the 1970s.

Sep 23, 2024 | psychiatrictimes.com | Heidi Anne Duerr |Sam Clark

CLINICAL CONVERSATIONSLater this month, the US Food and Drug Administration is scheduled to share results of the New Drug Application for Bristol Myers Squibb’s KarXT for the treatment of schizophrenia; the acceptance of the NDA was announced last year. As the date approaches, there is a growing sense of optimism for the drug and its novel mechanism of action, which could be the next breakthrough in the treatment of schizophrenia.

May 24, 2024 | psychiatrictimes.com | Leah Kuntz |Sam Clark

CLINICAL CONVERSATIONSTerran has announced the development of TerXT, a combination of xanomeline and trospium for the long-acting treatment of schizophrenia.1 TerXT has been submitted to the US Food and Drug Administration (FDA) for approval on the 505(b)(1) path with a decision expected by September 2024.2 To help share more on the announcement, Psychiatric Times sat down with Sam Clark, MD, PhD, the founder and CEO of Terran Biosciences. PT: Tell us a little about TerXT in your own words.